• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by ARCA biopharma Inc.

    4/29/24 7:28:44 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $ABIO alert in real time by email
    SC 13G 1 tm2412836d2_sc13g.htm SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

    ARCA biopharma, Inc.

    (Name of Issuer)

     

    Common stock, $0.001 par value per share

    (Title of Class of Securities)

     

    00211Y506

    (CUSIP Number)

     

    April 17, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

    xRule 13d-1(c)

    ¨Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 00211Y506 Page 2 of 17

     

    1.

    Names of Reporting Persons

     

    Venrock Healthcare Capital Partners III, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    754,669 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    754,669 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    754,669 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    5.2% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    PN

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    (2)Consists of (i) 164,442 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 16,450 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 573,777 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 14,501,143 shares of common stock outstanding as of January 31, 2024, as disclosed in the Issuer’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on February 1, 2024.

     

     

     

     

    CUSIP No. 00211Y506 Page 3 of 17

     

    1.

    Names of Reporting Persons

     

    VHCP Co-Investment Holdings III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    754,669 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    754,669 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    754,669 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    5.2% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    (2)Consists of (i) 164,442 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 16,450 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 573,777 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 14,501,143 shares of common stock outstanding as of January 31, 2024, as disclosed in the Issuer’s Annual Report on Form 10-K filed with the SEC on February 1, 2024.

     

     

     

     

    CUSIP No. 00211Y506 Page 4 of 17

     

    1.

    Names of Reporting Persons

     

    Venrock Healthcare Capital Partners EG, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    754,669 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    754,669 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    754,669 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    5.2% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    PN

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    (2)Consists of (i) 164,442 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 16,450 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 573,777 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 14,501,143 shares of common stock outstanding as of January 31, 2024, as disclosed in the Issuer’s Annual Report on Form 10-K filed with the SEC on February 1, 2024.

     

     

     

     

    CUSIP No. 00211Y506 Page 5 of 17

     

    1.

    Names of Reporting Persons

     

    VHCP Management III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    754,669 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    754,669 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    754,669 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    5.2% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    (2)Consists of (i) 164,442 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 16,450 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 573,777 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 14,501,143 shares of common stock outstanding as of January 31, 2024, as disclosed in the Issuer’s Annual Report on Form 10-K filed with the SEC on February 1, 2024.

     

     

     

     

    CUSIP No. 00211Y506 Page 6 of 17

     

    1.

    Names of Reporting Persons

     

    VHCP Management EG, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    754,669 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    754,669 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    754,669 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    5.2% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    (2)Consists of (i) 164,442 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 16,450 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 573,777 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 14,501,143 shares of common stock outstanding as of January 31, 2024, as disclosed in the Issuer’s Annual Report on Form 10-K filed with the SEC on February 1, 2024.

     

     

     

     

    CUSIP No. 00211Y506 Page 7 of 17

     

    1.

    Names of Reporting Persons

     

    Shah, Nimish

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    754,669 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    754,669 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    754,669 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    5.2% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    IN

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    (2)Consists of (i) 164,442 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 16,450 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 573,777 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 14,501,143 shares of common stock outstanding as of January 31, 2024, as disclosed in the Issuer’s Annual Report on Form 10-K filed with the SEC on February 1, 2024.

     

     

     

     

    CUSIP No. 00211Y506 Page 8 of 17

     

    1.

    Names of Reporting Persons

     

    Koh, Bong

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    754,669 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    754,669 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    754,669 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    5.2% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    IN

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    (2)Consists of (i) 164,442 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 16,450 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 573,777 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 14,501,143 shares of common stock outstanding as of January 31, 2024, as disclosed in the Issuer’s Annual Report on Form 10-K filed with the SEC on February 1, 2024.

     

     

     

     

    CUSIP No. 00211Y506 Page 9 of 17

     

    Item 1.
      (a)

    Name of Issuer

     

    ARCA biopharma, Inc.

     
      (b)

    Address of Issuer’s Principal Executive Offices

     

    10170 Church Ranch Way, Suite 100

    Westminster, CO 80021

     
    Item 2.
      (a)

    Name of Person Filing

     

    Venrock Healthcare Capital Partners III, L.P.

    VHCP Co-Investment Holdings III, LLC

    Venrock Healthcare Capital Partners EG, L.P.

    VHCP Management III, LLC

    VHCP Management EG, LLC

    Nimish Shah

    Bong Koh

     

      (b) Address of Principal Business Office or, if none, Residence
             
        New York Office: Palo Alto Office:  
             
        7 Bryant Park 3340 Hillview Avenue  
        23rd Floor Palo Alto, CA 94304  
        New York, NY 10018    

     
      (c)

    Citizenship

     

    All of the Venrock Entities were organized in Delaware. The individuals are both United States citizens.

     
      (d)

    Title of Class of Securities

     

    Common Stock, $0.001 par value

     
      (e)

    CUSIP Number

     

    00211Y506

     
    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
       
      Not applicable

     

     

     

     

    CUSIP No. 00211Y506 Page 10 of 17

     

    Item 4. Ownership  
           
      (a) Amount beneficially owned as of April 26, 2024:  

     

      Venrock Healthcare Capital Partners III, L.P.   754,669(1)
      VHCP Co-Investment Holdings III, LLC   754,669(1)
      Venrock Healthcare Capital Partners EG, L.P.   754,669(1)
      VHCP Management III, LLC   754,669(1)
      VHCP Management EG, LLC   754,669(1)
      Nimish Shah   754,669(1)
      Bong Koh   754,669(1)

     

      (b) Percent of class as of April 26, 2024:  

     

      Venrock Healthcare Capital Partners III, L.P.     5.2 % (2)
      VHCP Co-Investment Holdings III, LLC     5.2 % (2)
      Venrock Healthcare Capital Partners EG, L.P.     5.2 % (2)
      VHCP Management III, LLC     5.2 % (2)
      VHCP Management EG, LLC     5.2 % (2)
      Nimish Shah     5.2 % (2)
      Bong Koh     5.2 % (2)

     

      (c) Number of shares as to which the person has, as of April 26, 2024:  

     

        (i)     Sole power to vote or to direct the vote:

     

      Venrock Healthcare Capital Partners III, L.P.   0    
      VHCP Co-Investment Holdings III, LLC   0    
      Venrock Healthcare Capital Partners EG, L.P.   0    
      VHCP Management III, LLC   0    
      VHCP Management EG, LLC   0    
      Nimish Shah   0    
      Bong Koh   0    

     

        (ii)     Shared power to vote or to direct the vote as of April 26, 2024:

     

      Venrock Healthcare Capital Partners III, L.P.   754,669(1)
      VHCP Co-Investment Holdings III, LLC   754,669(1)
      Venrock Healthcare Capital Partners EG, L.P.   754,669(1)
      VHCP Management III, LLC   754,669(1)
      VHCP Management EG, LLC   754,669(1)
      Nimish Shah   754,669(1)
      Bong Koh   754,669(1)

     

     

     

     

    CUSIP No. 00211Y506 Page 11 of 17

     

        (iii)   Sole power to dispose or to direct the disposition of as of April 26, 2024:

     

      Venrock Healthcare Capital Partners III, L.P.   0  
      VHCP Co-Investment Holdings III, LLC   0  
      Venrock Healthcare Capital Partners EG, L.P.   0  
      VHCP Management III, LLC   0  
      VHCP Management EG, LLC   0  
      Nimish Shah   0  
      Bong Koh   0  

     

        (iv)   Shared power to dispose or to direct the disposition of as of April 26, 2024:

     

      Venrock Healthcare Capital Partners III, L.P.   754,669(1)
      VHCP Co-Investment Holdings III, LLC   754,669(1)
      Venrock Healthcare Capital Partners EG, L.P.   754,669(1)
      VHCP Management III, LLC   754,669(1)
      VHCP Management EG, LLC   754,669(1)
      Nimish Shah   754,669(1)
      Bong Koh   754,669(1)

     

    (1)Consists of (i) 164,442 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 16,450 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 573,777 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

        VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC. VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P. Messrs. Shah and Koh are the voting members of VHCP Management III, LLC and VHCP Management EG, LLC.

     

    (2)This percentage is calculated based upon 14,501,143 shares of common stock outstanding as of January 31, 2024, as disclosed in the Issuer’s Annual Report on Form 10-K filed with the SEC on February 1, 2024.

     

    Item 5. Ownership of Five Percent or Less of a Class
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   ¨
     
    Item 6. Ownership of More than Five Percent on Behalf of Another Person
       
      Not applicable
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
       
      Not applicable

     

    Item 8. Identification and Classification of Members of the Group
       
      Not applicable

     

     

     

     

    CUSIP No. 00211Y506 Page 12 of 17

     

    Item 9. Notice of Dissolution of Group
       
      Not applicable
     
    Item 10. Certification
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

     

     

     

     

    CUSIP No. 00211Y506 Page 13 of 17

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: April 29, 2024

     

    Venrock Healthcare Capital Partners III, L.P.   Venrock Healthcare Capital Partners EG, L.P.
         
    By: VHCP Management III, LLC   By: VHCP Management EG, LLC
    Its: General Partner   Its: General Partner
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory

     

    VHCP Co-Investment Holdings III, LLC  
       
    By: VHCP Management III, LLC  
    Its: Manager  
       
    By: /s/ Sherman G. Souther  
      Name: Sherman G. Souther  
      Its: Authorized Signatory  

     

    VHCP Management III, LLC   VHCP Management EG, LLC
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory

     

    Nimish Shah  
       
    /s/ Sherman G. Souther  
    Sherman G. Souther, Attorney-in-fact  

     

    Bong Koh  
       
    /s/ Sherman G. Souther  
    Sherman G. Souther, Attorney-in-fact  

     

     

     

     

    CUSIP No. 00211Y506 Page 14 of 17

     

    EXHIBITS

     

    A:Joint Filing Agreement

     

    B:Power of Attorney for Nimish Shah

     

    C:Power of Attorney for Bong Koh

     

     

     

     

    CUSIP No. 00211Y506 Page 15 of 17

     

    EXHIBIT A

     

    JOINT FILING AGREEMENT

     

    In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of ARCA biopharma, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.

     

    In evidence whereof, the undersigned have caused this Agreement to be executed on their behalf this 29th day of April, 2024.

     

    Venrock Healthcare Capital Partners III, L.P.   Venrock Healthcare Capital Partners EG, L.P.
         
    By: VHCP Management III, LLC   By: VHCP Management EG, LLC
    Its: General Partner   Its: General Partner
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory

     

    VHCP Co-Investment Holdings III, LLC  
       
    By: VHCP Management III, LLC  
    Its: Manager  
       
    By: /s/ Sherman G. Souther  
      Name: Sherman G. Souther  
      Its: Authorized Signatory  

     

    VHCP Management III, LLC   VHCP Management EG, LLC
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory

     

    Nimish Shah  
       
    /s/ Sherman G. Souther  
    Sherman G. Souther, Attorney-in-fact  

     

    Bong Koh  
       
    /s/ Sherman G. Souther  
    Sherman G. Souther, Attorney-in-fact  

     

     

     

     

    CUSIP No. 00211Y506 Page 16 of 17

     

    EXHIBIT B

     

    POWER OF ATTORNEY FOR NIMISH SHAH

     

    KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of David L. Stepp, Sherman G. Souther and Lisa D. Harris signing individually, the undersigned’s true and lawful attorney-in fact and agent to:

     

    (i)prepare execute and file, for and on behalf of the undersigned, any and all documents and filings that are required or advisable to be made with the United States Securities and Exchange Commission, any stock exchange or similar authority, under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations promulgated thereunder, including without limitation (a) any Joint Filing Agreement under Rule 13d-1(k) of the Exchange Act (or any successor provision thereunder), Schedule 13D and Schedule 13G (or any successor schedules or forms adopted under the Exchange Act ) and any amendments thereto in accordance with Section 13 of the Exchange Act and the rules thereunder, and (b) Forms 3, 4 and 5 and any amendments thereto in accordance with Section 16(a) of the Exchange Act and the rules thereunder; and

     

    (ii)take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

     

    The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of undersigned, is not assuming, nor is Venrock assuming, any of the undersigned’s responsibilities to comply with the Exchange Act, including without limitation Sections 13 and 16 of the Exchange Act.

     

    This power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file any form or document with respect to the undersigned’s holdings of and transactions in securities issued by a company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact, or (c) until such attorney-in-fact shall no longer be employed by VR Management, LLC (or its successor).

     

    IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 29th day of April, 2024.

     

    /s/ Nimish Shah  

     

     

     

     

    CUSIP No. 00211Y506 Page 17 of 17

     

    EXHIBIT C

     

    POWER OF ATTORNEY FOR BONG KOH

     

    KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of David L. Stepp, Sherman G. Souther and Lisa D. Harris signing individually, the undersigned’s true and lawful attorney-in fact and agent to:

     

    (i)prepare execute and file, for and on behalf of the undersigned, any and all documents and filings that are required or advisable to be made with the United States Securities and Exchange Commission, any stock exchange or similar authority, under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations promulgated thereunder, including without limitation (a) any Joint Filing Agreement under Rule 13d-1(k) of the Exchange Act (or any successor provision thereunder), Schedule 13D and Schedule 13G (or any successor schedules or forms adopted under the Exchange Act ) and any amendments thereto in accordance with Section 13 of the Exchange Act and the rules thereunder, and (b) Forms 3, 4 and 5 and any amendments thereto in accordance with Section 16(a) of the Exchange Act and the rules thereunder; and

     

    (ii)take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

     

    The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of undersigned, is not assuming, nor is Venrock assuming, any of the undersigned’s responsibilities to comply with the Exchange Act, including without limitation Sections 13 and 16 of the Exchange Act.

     

    This power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file any form or document with respect to the undersigned’s holdings of and transactions in securities issued by a company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact, or (c) until such attorney-in-fact shall no longer be employed by VR Management, LLC (or its successor).

     

    IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 29th day of April, 2024.

     

    /s/ Bong Koh  

     

     

     

    Get the next $ABIO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABIO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ABIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split

    WESTMINSTER, Colo., Aug. 29, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) ("ARCA") today announced completion of the merger with Oruka Therapeutics, Inc. ("Oruka") following ARCA's successful receipt of stockholder approval for all proposals related to the merger at a special meeting of stockholders on August 22, 2024. ARCA following the merger is referred to herein as the "combined company." As previously announced, the combined company will effect a reverse stock split of its common stock subsequent to the merger. Thomas A. Keuer, President of ARCA said, "We are pleased with the outcome of the special meeting and appreciate our stockholders' support for the merger with

    8/29/24 4:50:15 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics

    WESTMINSTER, Colo., Aug. 26, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) ("ARCA") today announced an update to the previously announced final amount of the special cash dividend (the "Special Dividend"), which will now equal $1.613 per share of ARCA's common stock, payable on August 28, 2024, to ARCA's stockholders of record as of August 26, 2024. The Special Dividend was declared by ARCA's Board of Directors on August 16, 2024, in connection with the previously announced merger (the "Merger") with Oruka Therapeutics, Inc. ("Oruka"), pursuant to the Agreement and Plan of Merger and Reorganization, dated April 3, 2024 (the "Merger Agreement"). The exact amount of the Special

    8/26/24 7:30:00 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics

    WESTMINSTER, Colo., Aug. 23, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) ("ARCA") today announced that its Board of Directors (the "Board") has approved a reverse stock split of ARCA's common stock at a ratio of 1-for-12. ARCA's common stock is expected to begin trading on a post-reverse stock split basis on The Nasdaq Global Market on September 3, 2024, under the new name Oruka Therapeutics, Inc. and under the new symbol "ORKA" following the anticipated closing of the merger with Oruka Therapeutics, Inc. (the "Merger"), with a new CUSIP number 687604108 and ISIN number US6876041087. The reverse stock split was approved by ARCA's stockholders at ARCA's special meeting of

    8/23/24 4:30:00 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ABIO
    Leadership Updates

    Live Leadership Updates

    View All

    ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update

    ARCA biopharma and Oruka Therapeutics announce Merger AgreementARCA biopharma appoints Thomas Keuer as President WESTMINSTER, Colo., April 25, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), (the "Company") a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2024 financial results and provided a corporate update. In April 2022, ARCA established a Special Committee of the board of directors (the "Board") of ARCA to conduct a comprehensive review of strategic alternatives. As part of the strategic review process, the Company explored potential strategic alterna

    4/25/24 4:15:00 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ABIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by ARCA biopharma Inc.

    SC 13D/A - Oruka Therapeutics, Inc. (0000907654) (Subject)

    9/13/24 4:57:00 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13D filed by ARCA biopharma Inc.

    SC 13D - Oruka Therapeutics, Inc. (0000907654) (Subject)

    9/6/24 5:08:49 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed by ARCA biopharma Inc.

    SC 13G - ARCA biopharma, Inc. (0000907654) (Subject)

    4/29/24 7:28:44 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ABIO
    SEC Filings

    View All

    ARCA biopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Oruka Therapeutics, Inc. (0000907654) (Filer)

    9/13/24 4:02:39 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    ARCA biopharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Leadership Update, Financial Statements and Exhibits, Results of Operations and Financial Condition, Material Modification to Rights of Security Holders, Changes in Registrant's Certifying Accountant, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Change

    8-K - Oruka Therapeutics, Inc. (0000907654) (Filer)

    9/5/24 5:18:25 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 425 filed by ARCA biopharma Inc.

    425 - ARCA biopharma, Inc. (0000907654) (Subject)

    8/26/24 7:53:54 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ABIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fairmount Funds Management Llc was granted 275,000 shares (SEC Form 4)

    4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

    9/13/24 4:55:08 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    New insider Fairmount Funds Management Llc claimed ownership of 2,936,922 shares (SEC Form 3)

    3 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

    9/6/24 5:07:49 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    New insider Turtle Cameron claimed ownership of 85,233 shares (SEC Form 3)

    3 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

    9/6/24 5:07:01 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ABIO
    Financials

    Live finance-specific insights

    View All

    ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split

    WESTMINSTER, Colo., Aug. 29, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) ("ARCA") today announced completion of the merger with Oruka Therapeutics, Inc. ("Oruka") following ARCA's successful receipt of stockholder approval for all proposals related to the merger at a special meeting of stockholders on August 22, 2024. ARCA following the merger is referred to herein as the "combined company." As previously announced, the combined company will effect a reverse stock split of its common stock subsequent to the merger. Thomas A. Keuer, President of ARCA said, "We are pleased with the outcome of the special meeting and appreciate our stockholders' support for the merger with

    8/29/24 4:50:15 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics

    WESTMINSTER, Colo., Aug. 26, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) ("ARCA") today announced an update to the previously announced final amount of the special cash dividend (the "Special Dividend"), which will now equal $1.613 per share of ARCA's common stock, payable on August 28, 2024, to ARCA's stockholders of record as of August 26, 2024. The Special Dividend was declared by ARCA's Board of Directors on August 16, 2024, in connection with the previously announced merger (the "Merger") with Oruka Therapeutics, Inc. ("Oruka"), pursuant to the Agreement and Plan of Merger and Reorganization, dated April 3, 2024 (the "Merger Agreement"). The exact amount of the Special

    8/26/24 7:30:00 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics

    WESTMINSTER, Colo., Aug. 23, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) ("ARCA") today announced that its Board of Directors (the "Board") has approved a reverse stock split of ARCA's common stock at a ratio of 1-for-12. ARCA's common stock is expected to begin trading on a post-reverse stock split basis on The Nasdaq Global Market on September 3, 2024, under the new name Oruka Therapeutics, Inc. and under the new symbol "ORKA" following the anticipated closing of the merger with Oruka Therapeutics, Inc. (the "Merger"), with a new CUSIP number 687604108 and ISIN number US6876041087. The reverse stock split was approved by ARCA's stockholders at ARCA's special meeting of

    8/23/24 4:30:00 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care